Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin [12-March-2019] TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , March 12, 2019 /PRNewswir
March 12, 2019
· 18 min read